Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.


Journal

Journal of neurosurgery
ISSN: 1933-0693
Titre abrégé: J Neurosurg
Pays: United States
ID NLM: 0253357

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 30 12 2022
accepted: 11 04 2023
medline: 4 12 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

Mutations in NF2 are the most common somatic driver mutation in sporadic meningiomas. NF2 mutant meningiomas preferentially arise along the cerebral convexities-however, they can also be found in the posterior fossa. The authors investigated whether NF2 mutant meningiomas differ in clinical and genomic features based on their location relative to the tentorium. Clinical and whole exome sequencing (WES) data for patients who underwent resection of sporadic NF2 mutant meningiomas were reviewed and analyzed. A total of 191 NF2 mutant meningiomas were included (165 supratentorial, 26 infratentorial). Supratentorial NF2 mutant meningiomas were significantly associated with edema (64.0% vs 28.0%, p < 0.001); higher grade-i.e., WHO grade II or III (41.8% vs 3.9%, p < 0.001); elevated Ki-67 (55.0% vs 13.6%, p < 0.001); and larger volume (mean 45.5 cm3 vs 14.9 cm3, p < 0.001). Furthermore, supratentorial tumors were more likely to harbor the higher-risk feature of chromosome 1p deletion (p = 0.038) and had a larger fraction of the genome altered with loss of heterozygosity (p < 0.001). Infratentorial meningiomas were more likely to undergo subtotal resection than supratentorial tumors (37.5% vs 15.8%, p = 0.021); however, there was no significant difference in overall (p = 0.2) or progression-free (p = 0.4) survival. Supratentorial NF2 mutant meningiomas are associated with more aggressive clinical and genomic features as compared with their infratentorial counterparts. Although infratentorial tumors have higher rates of subtotal resection, there is no associated difference in survival or recurrence. These findings help to better inform surgical decision-making in the management of NF2 mutant meningiomas based on location, and may guide postoperative management of these tumors.

Identifiants

pubmed: 37243548
doi: 10.3171/2023.4.JNS222929
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1648-1656

Auteurs

Joanna K Tabor (JK)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Joseph O'Brien (J)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Sagar Vasandani (S)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Shaurey Vetsa (S)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Haoyi Lei (H)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Muhammad I Jalal (MI)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Neelan J Marianayagam (NJ)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Lan Jin (L)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Miguel Millares Chavez (M)

Departments of1Neurosurgery.

Joseph Haynes (J)

Departments of1Neurosurgery.

Alper Dincer (A)

3Department of Neurosurgery, Tufts Medical Center, Boston, Massachusetts.

Kanat Yalcin (K)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Stephanie M Aguilera (SM)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Sacit Bulent Omay (SB)

Departments of1Neurosurgery.

Ketu Mishra-Gorur (K)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Declan McGuone (D)

2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.
4Pathology.

Saul F Morales-Valero (SF)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Robert K Fulbright (RK)

2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.
5Radiology and Biomedical Imaging, and.

Murat Gunel (M)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.
6Genetics, Yale School of Medicine, New Haven, Connecticut.

E Zeynep Erson-Omay (EZ)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Jennifer Moliterno (J)

Departments of1Neurosurgery.
2The Chênevert Family Brain Tumor Center, Smilow Cancer Hospital, New Haven, Connecticut; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH